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Abstract
Introduction: Pulmonary diseases due to non-tuberculous mycobacterium (NTM) lung infection in
HIV-negative patients are rarely described in the literature. Currently, NTM consist of more than 150
species, and they are globally ubiquitous in both natural and man-made environments.The objective
of this study was to define the most frequent species of NTM causing pulmonary disease in HIVnegative patients in the city of Buenos Aires, Argentina. The prevalence of pulmonary diseases
caused by NTM is difficult to determine since the isolation of NTM does not necessarily indicate
disease.
Methods: A retrospective review of all the respiratory cultures positive for NTM in the Bacteriology
Laboratory of Posadas Hospital between January 2010 and December 2015 was performed. 31
patients without Human Immunodeficiency Virus (HIV) from whom NTM was isolated in respiratory
samples, which fulfilled diagnostic criteria for NTM disease were included.
Results: The mean age was 50 years at the time of the diagnosis (SD ± 17.2); and 19 patients
(61.3%) were males. Mycobacterium kansasii was the most commonly isolated NTM (68%) followed
by Mycobacterium avium Complex (MAC) (19%). M. kansasii was the most common cause of
pulmonary infection by NTM in these HIV-negative patients. Cultures should be performed to identify
the species and to treat accordingly. 46% of the patients included in the study, there was no evidence
of risk factors. Only 32% of the subjects had respiratory comorbidities, and the most common
radiologic finding was cavitation (55%).
Discussion: Our study indicates that M. kansasii is the primary etiology of NTM pulmonary disease
in HIV-negative patients in our service area in Buenos Aires. This finding supports the consideration
that patients with symptoms compatible with pulmonary tuberculosis should also be evaluated for
NTM with appropriate acid-fast bacilli cultures, as treatment regimens differ vastly according to the
specific pathogen isolated, although clinical and radiographic presentations may have overlapping
features. The possibility of M. kansasii pulmonary disease or other NTM should be considered in
patients treated empirically for TB without appropriate clinical response.
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Introduction
The clinical interpretation of the presence of a non-tuberculous
mycobacterium (NTM) lung infection in respiratory samples
is challenging, unlike tuberculosis (TB) the isolation of an
NTM in a respiratory culture does not automatically imply
pathogenicity. Currently, NTM consist of more than 150 species,
and they are globally ubiquitous in both natural and man-made
environments [1]. In certain scenarios, the microorganism could
be a transient colonizer or even a contaminant generated at
the time of sample collection or processing in the laboratory.
The diagnosis of disease is based on clinical, radiological and
microbiological criteria [2].
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NTM are ubiquitous microorganisms with nearly 100 different
species found in soil and water. The fatty-acid and wax-rich
impermeable cell wall of the mycobacteria can form biofilm that
allow for adherence to solid substrates such as pipes and leaves,
allowing the organism to persist despite treatment with common
disinfectants, most notably chlorine based disinfectants [1, 3].
According to Nishiuchi, Iwamoto and Maruyama, the formation
of aerosols containing NTM arising from shower water, soil, and
pool water implies that these niches can be infection sources.
Furthermore, genotyping has shown that clinical isolates are
identical to environmental ones from household tap water,
bathrooms, potting soil, and garden soil [4]. There is no
evidence of person to person or zoonotic transmission despite
that mycobacteria can cause infection in both humans, livestock
and wildlife. Mycobacterium avium Complex (MAC) is the most
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common NTM cause of pulmonary disease worldwide [5].
It is difficult to compare the incidence and prevalence of
NTM diseases across geographic areas. Because reporting
NTM disease to public health authorities is not required in
most countries, studies of the incidence and prevalence of
NTM disease are performed differently in different countries.
To compare reports regarding changes in the incidence and
prevalence of NTM disease over time in a limited geographic
area, one must compare reports that used the same methods.
Many epidemiological reports and reviews have shown that
NTM disease have been increasing since the 1950s [1,6].
The clinical significance of NTM isolation is not always clear
and it is difficult to assess the incidence or prevalence of
NTM disease due to several factors, notably its difficulty in
differentiation from colonization. Although the detection
of NTM colonies has been increasing since the 1950s [6] it is
unclear why NTM disease have been increasing in humans.
There are several potential contributing factors, such as, (i) an
increase of mycobacterial infection sources in the environment,
(ii) an increase in susceptible individuals, such as those Human
Immunodeficiency Virus (HIV) positive, (iii) improvements in
detection methods and laboratory equipment sensitivities (iv)
an increasing life expectancy of those with chronic structural
pulmonary disease (v) an increased awareness of NTM diseases
[1,7].
In many countries, especially those in high-burden areas for TB,
the diagnosis of TB is mainly based on the detection of acid-fast
bacilli in a sputum smear, as well as on their symptoms and the
results of a chest X-ray [1]. Pulmonary diseases caused by NTM
could be presumptively treated as pulmonary tuberculosis (TB)
as the microbiologic smear of the sputum does not distinguish
NTM from TB, and the clinical manifestations are similar. In
Latin America the prevalence of NTM is estimated to be much
lower than that of TB. The incidence of tuberculosis in Argentina
is of 23,91/ 100,000 inhabitants with wide regional variations.
In the province of Buenos Aires, it is 30,27/100,000 inhabitants.
There are differences in the relative abundances of mycobacterial
species that cause NTM diseases across geographic areas, the
NTM distribution is most notably associated with variants
in environmental factors such as, soil and water distribution
systems [1,7]. Pulmonary diseases due to NTM in HIV-negative
patients are rarely described in the literature [8]. The objective
of this study was to define the most frequent species of NTM
causing pulmonary disease in HIV-negative patients in the city
of Buenos Aires, Argentina.

Materials and Methods
A retrospective review of all the respiratory cultures positive
for NTM in the Bacteriology Laboratory of Posadas Hospital
between January 2010 and December 2015 was performed.
Posadas Hospital is a high complexity hospital with 500
admission beds and a service area covering a population of
approximately 4,400,000. IRB approval was obtained for this
study.
Patients older than 15 years old that fulfilled the ATS/IDSA
diagnostic criteria for pulmonary disease due to NTM were
included in the study [2]. All patients in the study were screened
for HIV and we excluded those who presented with positive HIV
serology.

The method utilized to perform the cultures was the BACTEC
MGIT (fluorescence) in addition to solid culture media
(Lowenstein Jensen). Lateral flow immunoassay (LFA) were
performed on positive cultures to differentiate NTM from TB.
The following variables were analyzed: age, sex, NTM species,
and clinical and radiological characteristics. For the categorical
variables, we used percentages as frequency measurements.
The continuous variables were expressed as mean or median
depending on the sample distribution. Statistical analysis was
performed using the computing environment R version 3.4.3
software [9].

Results
From a total of 1205 positive cultures for mycobacteria, 113
(9.3%) correspond to NTM. 31 patients that fulfilled the
inclusion criteria were included in the analysis. M. kansasii was
isolated in 21 patients (67.7%), M. Avium Complex (MAC) was
isolated in 6 patients (19.3%), M. fortuitum was isolated in 2
patients (6.4%), M. abscessus was isolated in one patient (3.2%)
and M. chelonae was isolated in one patient as well (3.2%).
Culture samples were obtained from bronchoalveolar lavage
(BAL) and/or bronchial lavage in 21 patients (67.7%) and from
sputum in 10 patients (32.3 %). The mean age was 50 years at
the time of the diagnosis (SD ± 17.2); and 19 patients (61.3%)
were males.
In our series, 17 patients (55%) had some predisposing factor for
NTM disease. Ten patients (32.2%) had a previous pulmonary
disease: (a) radiologic sequela of TB was noted in 3 patients,
(b) Chronic Obstructive Pulmonary Disease (COPD) was
present in 2 patients, (c) pulmonary carcinoma was present
in another 2 patients, (d) asbestosis in 1 patient, (e) diffuse
interstitial pulmonary disease associated with Rheumatoid
arthritis in 1 patient and (f) cystic fibrosis were noted in 1
patient. Eleven patients (35%) had a history of smoking. We
found non-pulmonary comorbidities in four patients (12.9%):
(a) rheumatoid arthritis, (b) multiple sclerosis (MS), (c) Acute
myeloid leukemia (AML), (d) diabetes mellitus combined
with hemolytic anemia. Three of these patients were receiving
immunosuppressant. Four patients were older than 65 years
without evidence of any comorbidities. (Table 1)
Table 1 Patient characteristics in Posadas Hospital Buenos Aires,
Argentina (n=31)
Age
(mean age±SD)
Sex
Male
Female
Samples
Bronchoalveolar lavage
Sputum
Non-Pulmonary comorbidities
Refractory Anemia (RA)
Hemolytic anemia and Diabetes
Multiple Sclerosis (MS)
Acute myeloid leukemia (AML)
Pulmonary comorbidities
Chronic obstructive pulmonary disease (COPD)
Drug-induced pulmonary disease (DIPD)
TB Sequels
Asbestosis
Lung Cancer
Bronchiectasis
Cavitary infiltrate
Smoking
Threatening hemoptysis
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n=31 n (%)
50±17.5
19(61.3)
12(38.7)
21(67.7)
10(32.3)
1(3.2)
1(3.2)
1(3.2)
1(3.2)
2(6.4)
1(3.2)
3(9.6)
1(3.2)
2(6.4)
2(6.4)
17 (55)
11 (35.5)
2 (6.4)
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Figure 1 Substantial numbers of non-tuberculous mycobacteria (NTM) disease
patients have been found among suspected tuberculosis (TB) and chronic TB
patients worldwide [1].

The most frequent radiographic finding was pulmonary
cavitation, observed in 17 patients (55%). This finding was most
commonly associated with M. kansasii. Bronchiectasis was
noted in 2 patients, one of which had underlying cystic fibrosis.
(Table 1)
Three deaths were noted in the study population. Two deaths
were related to NTM disease and one was due to acute myeloid
leukemia. Two patients presented with fulminant hemoptysis
which resulting in death in one of the patients. All the patients
received treatment according to the American Thoracic Society
(ATS) guidelines [1].

Discussion
The majority of pulmonary disease due to NTM is caused by
slow-growing mycobacteria. The most commonly isolated
species is MAC followed by M. kansasii. Amongst the rapidgrowing mycobacteria, M. abscessus was the most commonly
isolated [2]. In our series, the most frequent isolated species
was M. kansasii, contrary to what has been previously described
in the literature. However, in Argentina and South America
in general, data on NTM prevalence is variable. Barnes et
al. described 75% of NTM isolates in pulmonary and extra
pulmonary samples as MAC and only 3% as M. kansasii in a
study including immunocompetent and immunocompromised
patients, in Buenos Aires [9]. Imperiale et al. described MAC
as the most frequently isolated NTM (32.2% of isolates) in
pulmonary and extra-pulmonary infections, with M. kansasii in
fourth place (8% of isolates) in a study which also included HIV
patients [11]. Mello et al. conducted a study in Brazil to identify
clinical and therapeutic features of pulmonary nontuberculous
mycobacterial disease which included patients with AIDS.
They found that M. kansasii was the most frequently isolated
organism (33.9%) and MAC the second one in frequency
(30.4%) [12].
The significant geographic variability in the distribution of M.
kansasii has also been observed in other areas of the world with
a high prevalence of pulmonary disease caused by this NTM in
western Europe, Switzerland, and the United Kingdom [8]. In
many countries, the most frequently reported mycobacterial
species is MAC. In Japan and Oregon, USA, MAC has been

reported to account for 88.8% of all cases of NTM diseases.
In Eastern Asia, MAC accounts for 68% of all cases of NTM
diseases. MAC was isolated more frequently in Northern Europe
(44% of all mycobacteria) than in Southern Europe (31%). MAC
was the most common species complex (64–85% of cases)
in North America, followed in most studies by M. abscessus/
chelonae (3–13%), M. xenopi (1–23%), M. fortuitum (<1–8%),
and M. kansasii (<1–6%). In Central and South America, MAC
was generally most common, and M. kansasii was also reported
frequently [1,8].
The transmission of MAC and other non-tuberculous
mycobacteria organisms are likely to be linked with human
activities. Global human mobility and trade may promote
the global transmission of MAC via fomites [1]. Climatic and
ecological factors (water, biofilm, residential soil and dust), as
well as the prevalence of comorbidities such as HIV infection,
likely have an impact on the prevalence of different NTM
species in each region. Bonnet et al. described water sources,
particularly well water, as an important reservoir for NTM
infection, in Cambodia [7].
The best-defined risk factors NTM infection are advanced age,
immunosuppression (including HIV infection), and pulmonary
disease (COPD, bronchiectasis, sequelae of previous TB,
cystic fibrosis, etc.) [7,13,14] Anti-TNF-α agents (infliximab,
etanercept, adalimumab), methotrexate and corticosteroids
use also constitute risk factors for NTM disease. Low body
mass index (BMI), skeletal abnormalities and gastroesophageal
reflux have also been described as predisposing factors to NTM
pathogenicity [15]. Children and teenagers rarely develop NTM
disease. in the absence of underlying cystic fibrosis. In our study,
the average age was 50 years old, less than the one described in
the studies conducted in Europe or the USA [8].
Okoi et al. performed a systematic review of NTM isolated in
respiratory samples in sub-Saharan Africa. In this review, the
average age was 35 years old, likely related to the high prevalence
rate of TB and a high rate of HIV coinfection in the region [16].
The clinical interpretation of the presence of NTM in respiratory
cultures is problematic, as, unlike TB, the isolation of NTM in
a respiratory sample does not imply pathogenicity. In certain
situations, the microorganisms can be a transient colonizer
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or contaminant. The diagnosis of the disease is based on
clinical, radiological and microbiological criteria [2]. In several
countries, such as Argentina, NTM disease is non-reportable
and therefore its incidence and prevalence are unknown. The
current available epidemiologic data on NTM infections in
Argentina is from a single institution, described in a study
by Barnes et al. and may not be representative of the entire
country or region [9]. Many developing countries, where TB is
presumed to be more prevalent than NTM (3.4–39%) (Figure
1) [1]. These TB prevalent countries follow their own established
guidelines for the management of positive acid-fast bacilli
cultures in a sputum smear, as well as on their symptoms and if
available the results of a chest X-ray. Their treatment guidelines
typically favor empiric therapy for TB and reserve more specific
organism determination for certain clinical situations, such as
suspected drug-resistant TB, TB treatment failures, children,
immunocompromised patients, mycobacteriosis retreatment,
health workers, prisoners, extra pulmonary disease, diabetes,
immigrants from areas of high multidrug resistant tuberculosis
rate and positive bronchoalveolar lavage and bronchial lavage
samples. However, NTM disease patients are not cured by
the 6-month anti-TB treatment and they are then potentially
considered to have chronic or multidrug resistant TB. This
then results in NTM patients who do not receive appropriate
treatment for their NTM disease, annual TB reports that contain
errors; and unnecessary expenses for TB treatments. Thus, a
reliable, low-cost mycobacterial diagnostic method that results
in species-level identification is urgently required [1].
The small sample size our study is a limitations, as well as the
lack of surveillance for pulmonary NTM hinders the ability
to test these hypotheses and ultimately prevent infection. In
addition, our study samples were all collected at the same
institution and may not be representative of other national or
regional data. Furthermore, cultures were not obtained from all
the samples, and environmental and occupational variables was
not collected. One of the strengths of our study was that only
patients who meet disease criteria were included and also HIVpositive patients were excluded allowing for an estimation of the
prevalence of NTM disease in an immunocompetent population.
There has been a global improvement in the ability to
recognize NTM as human pathogens. Technological advances
in laboratory methods have, in addition, allowed faster and
more accurate identification of different NTM species and their
antimicrobial susceptibilities. These factors have contributed
to a more tailored approach to management, in alignment with
established international guidelines for treatment of specific
NTM infection.
In conclusion, our study indicates that M. kansasii is the
primary etiology of NTM pulmonary disease in HIV-negative
patients in our service area in Buenos Aires, Argentina.
This finding supports the consideration that patients with
symptoms compatible with pulmonary tuberculosis should
also be evaluated for NTM with appropriate acid- fast bacilli
cultures, as treatment regimens differ vastly according to the
specific pathogen isolated, although clinical and radiographic
presentations may have overlapping features. The possibility
of M. kansasii pulmonary disease or other NTM should be
considered in patients treated empirically for TB without
appropriate clinical response.
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